Nymox Pharmaceutical (Nymox Pharmaceutical) Debt-to-Equity : -0.01 (As of Sep. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Debt-to-Equity?

Nymox Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.01 Mil. Nymox Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Nymox Pharmaceutical's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-1.90 Mil. Nymox Pharmaceutical's debt to equity for the quarter that ended in Sep. 2023 was -0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nymox Pharmaceutical's Debt-to-Equity or its related term are showing as below:

NYMXF' s Debt-to-Equity Range Over the Past 10 Years
Min: -30.92 Med: -0.16 Max: 61.44
Current: -0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Nymox Pharmaceutical was 61.44. The lowest was -30.92. And the median was -0.16.

NYMXF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs NYMXF: -0.01

Nymox Pharmaceutical Debt-to-Equity Historical Data

The historical data trend for Nymox Pharmaceutical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Debt-to-Equity Chart

Nymox Pharmaceutical Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.20

-0.77

-0.36

Nymox Pharmaceutical Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.29	-0.36	-0.06	-0.28	-0.01

Competitive Comparison of Nymox Pharmaceutical's Debt-to-Equity

For the Biotechnology subindustry, Nymox Pharmaceutical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nymox Pharmaceutical's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Debt-to-Equity falls into.

Nymox Pharmaceutical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nymox Pharmaceutical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.173	+	0)	/	-0.482
	=	-0.36

Nymox Pharmaceutical's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.011	+	0)	/	-1.902
	=	-0.01

Nymox Pharmaceutical (OTCPK:NYMXF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nymox Pharmaceutical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bay & Deveaux Streets, Nassau, BHS

Website

https://www.nymox.com

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.

Executives

James George Robinson	director	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen	officer: Chief Financial Officer	9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback	director, 10 percent owner, officer: CEO	C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham	director, officer: General Counsel